Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis

Bibliographic Details
Main Author: Won Seop Kim
Format: Article
Language:English
Published: Korean Pediatric Society 2013-06-01
Series:Korean Journal of Pediatrics
Online Access:http://kjp.or.kr/upload/pdf/kjped-56-269.pdf
_version_ 1818518185296527360
author Won Seop Kim
author_facet Won Seop Kim
author_sort Won Seop Kim
collection DOAJ
first_indexed 2024-12-11T01:06:34Z
format Article
id doaj.art-4f6dd329d9fb4b86951649fdd130e420
institution Directory Open Access Journal
issn 1738-1061
2092-7258
language English
last_indexed 2024-12-11T01:06:34Z
publishDate 2013-06-01
publisher Korean Pediatric Society
record_format Article
series Korean Journal of Pediatrics
spelling doaj.art-4f6dd329d9fb4b86951649fdd130e4202022-12-22T01:26:09ZengKorean Pediatric SocietyKorean Journal of Pediatrics1738-10612092-72582013-06-0156626926910.3345/kjp.2013.56.6.26920125550420Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosisWon Seop Kim0Department of Pediatrics, Chungbuk National University, College of Medicine, Cheongju, Korea.http://kjp.or.kr/upload/pdf/kjped-56-269.pdf
spellingShingle Won Seop Kim
Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
Korean Journal of Pediatrics
title Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
title_full Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
title_fullStr Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
title_full_unstemmed Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
title_short Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
title_sort retraction mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
url http://kjp.or.kr/upload/pdf/kjped-56-269.pdf
work_keys_str_mv AT wonseopkim retractionmammaliantargetofrapamycininhibitorsfortreatmentintuberoussclerosis